<DOC>
	<DOCNO>NCT01561157</DOCNO>
	<brief_summary>The objective protocol conduct longitudinal multidisciplinary investigation human porphyria include natural history , morbidity , pregnancy outcome , mortality people disorder .</brief_summary>
	<brief_title>Longitudinal Study Porphyrias</brief_title>
	<detailed_description>The porphyria group rare metabolic disease may present childhood adult life due deficiency enzymes heme biosynthetic pathway . The common manifestation related accumulation intermediate pathway usually occur acute neurological attack , cutaneous photosensitivity . Multiple mutation identify porphyria . The risk disability death disorder significant , part diagnosis often delay due lack adoption diagnostic test clinical practice . Moreover , natural history disorder well describe know determines difference outcomes . New therapy need . For exist therapy , high-quality evidence short long term efficacy safety generally lack . Therefore , purpose long-term follow-up study large group patient various porphyrias provide good understanding natural history disorder , affect available therapy , aid develop new form treatment . The Office Rare Diseases ( ORD ) National Institutes Health ( NIH ) establish Rare Diseases Clinical Research Network ( RDCRN ) collaboration NIH Institutes currently fund 19 rare disease clinical research consortium one Data Management Coordinating Center . The Porphyrias Consortium create part RDCRN , study human porphyria . The Porphyrias Consortium consortium academic institution list participate institution table . All Centers Porphyrias Consortium participate Longitudinal Study Porphyrias . Additional center may add funding available . The initial objective protocol assemble well-documented group patient confirm diagnosis specific porphyrias clinical , biochemical , genetic study . The long-term objective conduct longitudinal investigation natural history , complication , therapeutic outcome people acute cutaneous porphyria .</detailed_description>
	<mesh_term>Porphyrias</mesh_term>
	<mesh_term>Porphyria , Erythropoietic</mesh_term>
	<mesh_term>Porphyria , Acute Intermittent</mesh_term>
	<criteria>Individuals document diagnosis porphyria . For type porphyria , inclusion criterion base clinical feature ; biochemical finding , document laboratory report ( copy ) porphyriaspecific test perform 1980 ( Absolute value prefer diagnostic biochemical threshold . Fold increase comparison upper ( low ) limit normal ( ULN LLN ) also acceptable , complicate considerable variation laboratory normal limit . Equivocal biochemical measurement may require confirmation consortium reference laboratory ; ) molecular finding document identification mutation porphyriarelated gene . In addition , individual parent guardian must willing give write informed consent assent , appropriate . Provision make enrol relative may symptoms biochemical molecular documentation porphyria , case recessive disorder carry diseaserelated mutation . Cases elevation porphyrin urine , plasma erythrocyte due disease ( i.e . secondary porphyrinuria porphyrinemia ) , liver bone marrow disease ; Patients prior diagnosis porphyria document review exist medical record repeat biochemical DNA testing .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>porphyria</keyword>
	<keyword>acute intermittent</keyword>
	<keyword>coproporphyria</keyword>
	<keyword>variegate</keyword>
	<keyword>erythropoietic</keyword>
	<keyword>protoporphyria</keyword>
	<keyword>hepatoerythropoietic</keyword>
	<keyword>cutanea tarda</keyword>
	<keyword>AIP</keyword>
	<keyword>HCP</keyword>
	<keyword>VP</keyword>
	<keyword>ADP</keyword>
	<keyword>ALAD</keyword>
	<keyword>PCT</keyword>
	<keyword>HEP</keyword>
	<keyword>CEP</keyword>
	<keyword>EPP</keyword>
	<keyword>XLP</keyword>
</DOC>